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abstRact
IntroductIon: The treatment of women with ovarian can­
cer in advanced stages consists of extensive surgery fol­
lowed by chemotherapy initiated three weeks after surgery. 
In this study, selected immune parameters were investi­
gated to elucidate when the immune system is normalised 
 following the operation.
Methods: Ten women undergoing extensive surgery for 
ovarian cancer were compared with a control group of ten 
women undergoing abdominal hysterectomy for a benign 
diagnosis. Blood samples were collected over a period of 21 
days post­operatively. The levels of interleukin­6, interleu­
kin­8, interleukin­10 and the activity and total frequency of 
natural killer cells were measured.
results: Interleukin­6 and interleukin­10 were significantly 
elevated immediately after the operation and also after 21 
days. The total population of natural killer cells and the to­
tal activity were reduced. The total activity of natural killer­
cells did not normalise within 21 days.
conclusIons: The level of the cytokines interleukin­6 and 
interleukin­10 is increased 21 days after the operation, and 
the function of natural killer cells is not normalised at 21 
days after surgery.
FundIng: The study received funding from Odense Univer­
sity Hospital Free Research Fund.
trIal regIstratIon: not relevant.
The survival of women with ovarian cancer (OC) in ad­
vanced stages (stages IIIa­c and IV, according to The Inter­
national Federation of Gynaecology and Obstetrics) has 
improved considerably over the past ten years. The treat­
ment has changed from either traditional surgery or 
chemotherapy to a combination of both treatment op­
tions offering the affected women extensive surgery fol­
lowed by chemotherapy [1­3]. Extensive surgery includes 
hysterectomy and bilateral salpingo­oophorectomy, peri­
tonectomy, resection of parts of the colon or the small in­
testine and splenectomy in cases with macroscopic me­
tastasis visible on the spleen. All para­aortic and pelvic 
lymph nodes are removed if metastases are suspected. 
In Denmark, the treatment protocol dictates that 
chemotherapy should be initiated three weeks post­ 
operatively (PO) unless the white blood cell count (WBC) 
is reduced.
Two theories have been proposed in relation to the 
effect of surgery followed by chemotherapy. The first 
theory is that resection diminishes the amount of tu­
mour cells which enhances the cytotoxicity of chemo­
therapy in relation to the residual cancer. The second 
theory is that the tumour cells induce immunosuppres­
sion and thus enhance a vicious circle with tumour 
growth suppressing the remaining immune system. 
Extensive surgery reduces the tumour burden and thus 
slows this vicious circle [4]. The effect observed after ex­
tensive surgery is probably a combination of both.
In order to elucidate the changes in the immune 
system in women undergoing extensive surgery, we ana­
lysed their immune system and compared changes with 
changes encountered in women undergoing abdominal 
hysterectomy due to benign disease.
The following immune parameters of special rele­
vance to the innate immune system were chosen to de­
scribe the immune profile: Interleukin (IL) 6, IL­8, IL­10 
and natural killer (NK) cells. 
Il­6 is a pleiotropic cytokine that acts in a pro­in­
flammatory way by attracting neutrophils to the area 
where damage has occurred. Moreover, it promotes the 
upregulation of adhesion molecules and L­selectin. IL­6 
also stimulates the hepatic acute­phase protein synthe­
sis with release of C­reactive protein and procalcitonin. 
Furthermore, Il­6 stimulates the production of prosta­
glandin E2 which, in turn, stimulates the secretion of IL­
10 production. In addition, IL­6 has its own direct anti­ 
inflammatory properties. The secretion of IL­6 correlates 
with the magnitude of the trauma and the duration of 
surgery, and elevated levels of IL­6 increase the risk of 
post­operative complications. Elevated IL­6 serum levels 
in patients with OC are correlated with shorter relapse­
free periods and overall poor survival [5].
IL­8 plays an important role in inflammation as it re­
cruits T­cells and accelerates wound healing. In several 
studies, the presence of IL­8 in women with OC has been 
correlated with a poor outcome [6]. IL­8 is produced by 
monocytes, neutrophils and epithelial cells, but also by 
the tumour cells. 
IL­10 is responsible for T helper cell proliferation.  
IL­10 also hampers the maturation of dendritic cells and 
hinders the function of co­stimulatory molecules. 
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Previous investigations have shown that women with OC 
have higher levels of IL­10, and IL­10 has been suggested 
as a good surrogate marker for tumour grading [7].
NK cells comprise a subtype of lymphocytes that are 
important mediators of the innate immunity and have 
the ability to secrete cytokines and interferon gamma 
(IFN­γ), among others, and chemokines, and to kill in­
fected or transformed cells, i.e. cancer cells [8, 9].
NK cells are believed to play a crucial role in the de­
fence against cancer.
Our hypothesis was that in women with OC stage 
III­IV who have been exposed to extensive surgery, the 
immune system does not return to preoperative status 
within 21 days.
mEthOds
The study was carried out in Odense University Hospital, 
the Region of Southern Denmark. The Regional Scientific 
Ethical Committees for Southern Denmark approved the 
protocol (No. S­20080076). 
interleukin 6, interleukin 8 and interleukin 10
Plasma and serum samples were centrifuged, separated 
and frozen at –80 °C.
The samples were analysed using Human IL­6 ELISA 
BD, Human IL­8 ELISA BD, and Human IL­10 ELISA BD (all 
Becton Dickinson, Franklin Lakes, NJ, USA) according to 
the manufacturer’s instructions.
natural killer cells
NK cells cannot be separated directly from whole blood. 
However, as mononuclear cells (MNC) also contain NK 
cells, we separated MNC from whole blood as described 
by Boyum [10]. Whole blood was centrifuged with Ficoll­
Paque(GE Healthcare Life Sciences, Buckinghamshire, 
UK) , a density medium, in order to isolate MNC. The iso­
lated MNC were then cryopreserved at –135 °C.
The activity of NK cells within the MNC cell pool was 
analysed using a 51Cr­release assay [11]. The following 
procedure was performed when all blood samples were 
collected. 
Briefly, the theory is that when exposed to harmful 
cells, NK cells will destroy them. In this assay, K562, a 
population of chronic myeloid blast cell, was labelled 
with 51Cr. The K562 cells were labelled passively by diffu­
sion of 51Cr across the cellular membrane. The suspen­
sion with the labelled K 562 was then subjected to the 
rapidly thawed MNC, which contains NK cells. MNC and 
K562 cells were now incubated in order for the cytotox­
icity reaction to take place. If the NK cells were active, 
they would kill the K562 cells during the incubation time. 
This attack would destroy the cell wall and provoke the 
release of the radioactive 51Cr. The magnitude of radio­
activity in the supernatant of the assay was then meas­
ured.
The activity of the NK cells was calculated as:
Activity of NK cells (%) =  
experimental release – spontaneous release  
maximum release – spontaneous release 
× 100
In order to quantify the NK cells, the remaining frozen 
MNC were thawed and analysed by flow cytometry us­
ing the directly conjugated MoAbs: anti­CD19 to identify 
B lymphocytes, anti­CD3 for T lymphocytes and anti­
CD56 to identify NK cells. A blocking buffer was added. 
CD19 is a surface marker for B­cells. CD56 is surface 
marker for NK cells and some malignant cell lines; CD3 is 
the surface marker for T­cells.
The samples were analysed in a flow cytometer 
(Becton Dickinson FACS, Calibur, USA) at wavelength 488 
nm or 635 nm lasers.
Forward and side scatter was performed.
Graph Pad Prism (La Jolla, CA, USA) was used for 
statistical analyses. In order to test differences between 
groups, the Mann­Whitney test was applied. For com­
parisons within the group, one­way variance analysis 
was performed. Differences were considered significant 
when p­values were below 0.05.
A summary of study details is shown in table 1.  
Trial registration: not relevant.
tablE 1
Summary of study details.  
type of operation Extensive ovarian cancer  surgery abdominal hysterectomy
Disease Ovarian cancer FIGO stage III­IV  
which was estimated operable 
The judgement was made on the  
background of a magnetic resonance 
and computed tomography
Benign disease, only women 
scheduled for abdominal  
hysterectomy on benign  
basis, e.g. fibroids or benign  
metrorrhagia
Mode of anaesthesia General anaesthesia with epidural General anaesthesia  
without epidural
Recovery Intensive care unit Recovery room
Blood samples, day no. 0, 1, 2, 8, 21 0, 1, 2, 8, 21
Chemotherapy start,  
day no.
All on day 20­22 –
ASA classification 1­2 1­2
Exclusion criteria Immunological disease, e.g.  
rheumatoid arthritis, systemic  
lupus erythematous 
Patients already diagnosed with cancer
Immunological disease,  
e.g. rheumatoid arthritis,  
systemic lupus erythe matous 
Patients already diagnosed 
with cancer
Age, yrs > 18 > 18
Analysed immune markers IL­6, IL­8, IL­10  
NK cells
IL­6, IL­8, IL­10  
NK cells
Patients, n 10 10
30­day mortality, n 0 0
ASA = American Society of Anesthesiologists; FIGO = International Federation of Gynecology and  
Obstetrics; IL = interleukin; NK = natural killer.
Dan Med J 63/6  June 2016 da n i s h m E d i c a l J O U R n a l   3
REsUlts 
A total of 20 women were included in the study. Three 
patients were excluded in the OC group; one patient 
turned out to be inoperable, while two patients were in­
correctly diagnosed initially (one had benign cysts on the 
ovaries, and one patient was diagnosed with a signet cell 
cancer). In the abdominal hysterectomy (H) group, seven 
patients completed the study, as three patients in the H 
group did not wish to have the last blood samples taken. 
The groups were comparable with regard to age, body 
mass index (BMI), coexisting diseases and total WBC.
The blood sampling was carried out from November 
2008 to May 2010.
By 1 January 2013, only one patient from the OC 
group had died. The follow­up period thus spanned from 
two years and five months to five years and one month.
interleukin 6, 8, 10
We found a significant difference between the OC group 
and the H group, the OC group having the highest levels 
of both IL­6 and 10 at day 1 and day 21 PO (Figure 1A 
and Figure 1C).
Moreover, IL­8 levels in the OC group significantly 
increased during the observation period. Although the 
levels of IL­8 were generally higher in the OC group, no 
significant difference was found between the groups 
(Figure 1B).
natural killer cell frequency and activity
Preoperatively, no difference in either NK cell activity or 
total number of NK cells was found between groups H 
and OC. Within the H group, the operation did not im­
pact this finding as no difference in the total number or 
in the total activity of NK cells occurred in the observa­
tion period. In the OC group, however, the activity of NK 
cells did not change, but as both the total lymphocyte 
count was diminished and the fraction of NK cells in the 
lymphocyte pool was reduced at PO day 21, the total  
NK cell activity was reduced in this group at PO day 21 
(Figure 2A­D).
discUssiOn
Previous studies of IL­6 levels in women with OC have 
been performed in women with OC stages FIGO I­II [5] 
which are less advanced stages than the ones included 
in our study and thus their results are not directly com­
parable with those of our population (FIGO stages III­IV). 
In more recent studies, ascites of women with OC was 
analysed in order to describe the levels of IL­6 and other 
cytokines [12, 13]. The biology of IL­6 in ascites is differ­
ent than in blood as the ascites is not exposed to the  
innate immune system, and therefore tends to have 
higher levels of cytokines.
The conclusion in all these studies is that there is a 
correlation between elevated levels of IL­6 and the pa­
tients’ outcome. In our study, we found significant dif­
ferences in the levels of IL­6 between the OC group and 
the control group – with especially high levels of IL­6 in 
FigURE 1
Interleukin (IL)­6 (a), IL­8 (b) and IL­10 (c) concentrations in blood on 
post­operative days 0, 1, 8 and 21. Median values and 95% confidence 
 intervals.
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the OC group on the 21st post­operative day. The high 
levels at day 1 may, in part, be explained by the recent 
surgery.
We interpret the elevated IL­6 levels as a possible 
combination of regrowth of the microscopic residual 
ovarian tumour cells in numbers that are sufficient to 
arouse the innate immune system, production of IL­6 
from residual ovarian tumour cells [14] that now have 
reached a number that can produce IL­6 in measurable 
amounts, and finally a cessation of the temporary post­
operative immune paralysis that always occurs after sur­
gery.
We have not been able to confirm the association 
found by other researchers linking high IL­8 levels with a 
poor outcome in women with OC [6, 15]. However, our 
study differs from other studies as we only examined 
women in stage III­IV, and the OC patients in our study 
underwent surgery.
In relation to IL­10, it is interesting to see how the 
levels are normalised at day 8 PO, and then escalate rap­
idly at 21 PO in the OC group. The normalisation of IL­10 
levels at day 8 PO corresponds with the results found by 
Mustea et al [16].
We were unable to investigate any correlation be­
tween the post­operative tumour load and the levels of 
IL­10 as all our patients were considered to have been 
radically operated (all macroscopic tumour tissue re­
moved). 
We speculate that on post­operative day 21, the 
amount of microscopically residual tumour tissue has 
reached a level where the tumour cells may again begin 
to produce IL­10. This is backed by findings reported by 
Rabinovich et al that OC cells with a high degree of cer­
tainty produce IL­10 [17]. Another explanation may be 
that the measured IL­10 is an indicator that the innate im­
mune system is aroused again, corresponding to the ris­
FigURE 2
Natural killer (NK) cell  
frequency and activity 
on post­operative days 
0, 1, 8 and 21: activity 
(a), total activity (b), 
total concentration of 
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of lym phocytes (d). 
Median values and 95% 
confidence intervals.
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ing levels of IL­6, as IL­6 induces the production of IL­10.
In our study, the activity and the total number of 
NK cells did not increase from day 8 to day 21. Uchida et 
al [18] reported that the activity of NK cells was normal­
ised three days after abdominal surgery for non­malig­
nant diseases, while the activity of NK cells was reduced 
for up to two weeks following breast cancer surgery. 
With a three­week­long suppression of the NK cell activ­
ity, our results are thus not unexpected.
limitations 
The limitation of our study is the small sample size. The 
processing of the immunological samples, however, was 
complex, expensive and time­consuming which ren­
dered it impossible to study the immune status in a  
larger population. In addition, we are aware of the fact 
that not all immunological aspects have been taken in to 
account; specifically, we have not measured IFN­γ. IFN­γ 
can give an indication of the activity and amount of NK 
cells. This was a deliberate choice as IFN­γ has a short 
half­life, which makes it very difficult to obtain the per­
fect time to collect blood samples and, if the timing is 
not correct, it becomes difficult to compare circulating 
levels of this cytokine.  
cOnclUsiOns
The existing policy concerning initiation chemotherapy 
following extensive surgery for OC in stage III­IV is to 
commence chemotherapy on the 21st post­operative 
day. The reason for this delay has been a belief that a 
patient’s immune system has returned to its preopera­
tive status after a 21­day interval. Our study shows that 
this is not the case; and thus there is no basis for delay­
ing chemotherapy. The women subjected to extensive 
surgery for OC demonstrated elevated levels of both IL­6 
and IL­10 at 21 post­operative days. This may suggest 
that the inflammatory response is still in progress or 
that regrowth of OC cells has taken place. As the total 
activity of NK cells is reduced at 21 days PO, this poten­
tially leaves these patients without sufficient ability to 
combat cancer cells. As a recent study by Lydiksen et al 
[19] showed that initiation of chemotherapy after day 
32 following OC surgery implicated a poorer five­year 
survival, an intuitive approach would be to commence 
chemotherapy earlier.
Our results, which do not support delaying chemo­
therapy, may open the possibility of initiating chemo­
therapy even before day 21 as the innate immune sys­
tem is back to its preoperative standard at that time 
anyhow. 
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